Press Releases

 

Washington, D.C. – Today, U.S. Congressman Lloyd Doggett (D-TX), called on the Centers for Medicare and Medicaid Services (CMS) to provide information on their outcomes-based payment approach for Novartis’ new chimeric antigen receptor T-cell (CAR-T) treatment, known as Kymriah. Rep. Doggett said:

Washington, D.C. – Today, U.S. Congressman Lloyd Doggett (D-TX), who represents a number of “Dreamers” in San Antonio, Austin, and San Marcos, issued the following response to Attorney General Jeff Sessions’s announcement ending the Deferred Action Childhood Arrival (DACA) program in six months, jeopardizing the legal status of approximately 800,000 Dreamers in the United States. Rep. Doggett said:

Washington, D.C. – Today, U.S. Congressman Lloyd Doggett (D-TX) issued the following statement after Texas Attorney General Ken Paxton announced that he is appealing the unanimous finding of a three-judge panel of federal judges that the State’s congressional map intentionally discriminated and violated the Constitution.

Washington, D.C. – Today, U.S. Congressman Lloyd Doggett (D-TX), senior member of the House Ways and Means Committee and chair of the Prescription Drug Task Force, issued the following statement after Trump’s Department of Justice agreed to settle charges against Mylan’s EpiPen rebate misclassification for $465 million. The misclassification could have cost taxpayers to overpay as much as $1.27 billion from 2006 to 2016, according to an estimate from the Department of Health and Human Services’ Office of the Inspector General.